Inclusion Criteria:

          -  B-cell non-Hodgkin lymphoma (NHL) including RT and transformed FL, that warrants
             systemic therapy

          -  Chronic Lymphocytic Leukemia (CLL), that warrants systemic therapy as defined by iwCLL
             (Hallek 2018)

          -  Treatment Status:

               1. NHL subjects: relapsed to or refractory after at least two prior standard
                  systemic therapies (excluding antibiotics)

               2. RT subjects: must have relapsed after or be refractory to at least two prior line
                  of therapy for CLL/SLL or RT

               3. CLL subjects: relapsed to or refractory after at least two prior standard
                  therapies

          -  Measurable disease defined as:

               1. NHL (including SLL): at least 1 measurable disease lesion > 1.5 cm

               2. CLL: at least 1 measurable disease lesion

        Exclusion Criteria:

          -  Prior therapy with any agent blocking the CD47/SIRPα pathway or any previous CD19
             targeting therapy,

          -  Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy,
             immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization)
             or any investigational drug within 21 days of Day 1 of Cycle 1

          -  Prior autologous SCT within 6 months.